
Company valuation, historical trends, and peer comparisons.
According to NextCure, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 14.84M. This represents a change of -30.36% compared to the average of 21.31M of the last 4 quarters.
The mean historical Enterprise Value of NextCure, Inc. over the last ten years is 233.94M. The current 14.84M Enterprise Value has changed -93.66% with respect to the historical average. Over the past ten years (40 quarters), NXTC's Enterprise Value was at its highest in in the December 2018 quarter at 2.26B. The Enterprise Value was at its lowest in in the March 2025 quarter at -2541793.60.
Average
233.94M
Median
153.36M
Minimum
-221929.50
Maximum
855.17M
Discovering the peaks and valleys of NextCure, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 169.40%
Maximum Annual Enterprise Value = 855.17M
Minimum Annual Increase = -8888.98%
Minimum Annual Enterprise Value = -221929.50
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 19.51M | -8888.98% |
| 2024 | -221929.50 | -100.88% |
| 2023 | 25.26M | 28.78% |
| 2022 | 19.61M | -87.21% |
| 2021 | 153.36M | -43.37% |
| 2020 | 270.80M | -68.33% |
| 2019 | 855.17M | 169.40% |
| 2018 | 317.44M | -28.60% |
The current Enterprise Value of NextCure, Inc. (NXTC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
14.85M
5-year avg
43.50M
10-year avg
233.94M
NextCure, Inc.’s Enterprise Value is less than Q32 Bio Inc. (160.40M), greater than Plus Therapeutics, Inc. (11.26M), less than Boundless Bio, Inc. (35.06M), less than Verrica Pharmaceuticals Inc. (52.28M), less than AN2 Therapeutics, Inc. (121.34M), greater than Jasper Therapeutics, Inc. (10.92M), greater than Intensity Therapeutics, Inc. (-55215.00), less than Pluri Inc. (44.55M), less than TAO Synergies Inc. (20.40M), less than Iterum Therapeutics plc (25.39M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 160.40M | $261.38M | |
| 11.26M | $9.36M | |
| 35.06M | $55.28M | |
| 52.28M | $61.67M | |
| 121.34M | $165.66M | |
| 10.92M | $17.96M | |
| -55215.00 | $9.38M | |
| 44.55M | $13.16M | |
| 20.40M | $22.77M | |
| 25.39M | $1.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NextCure, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NextCure, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is NextCure, Inc.'s Enterprise Value?
What is the highest Enterprise Value for NextCure, Inc. (NXTC)?
What is the 3-year average Enterprise Value for NextCure, Inc. (NXTC)?
What is the 5-year average Enterprise Value for NextCure, Inc. (NXTC)?
How does the current Enterprise Value for NextCure, Inc. (NXTC) compare to its historical average?